欧康医药
(920230)
| 流通市值：4.73亿 | | | 总市值：10.07亿 |
| 流通股本：4724.78万 | | | 总股本：1.00亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 7,318,996.17 | 18,231,894.92 | 9,099,349.82 | 6,024,252.63 |
| 交易性金融资产 | 29,536,699.36 | 17,608,446.58 | 51,682,275.57 | 32,558,837.4 |
| 应收票据及应收账款 | 79,726,641.4 | 83,986,985.61 | 72,786,100.93 | 104,826,078.94 |
| 其中：应收票据 | 752,631.19 | 4,683,224.2 | 368,431.87 | 1,203,618.63 |
| 应收账款 | 78,974,010.21 | 79,303,761.41 | 72,417,669.06 | 103,622,460.31 |
| 应收款项融资 | - | 7,597,665.97 | 594,544.05 | 248,321.05 |
| 预付款项 | 13,497,095.41 | 11,494,203.85 | 11,862,641.26 | 8,176,755.84 |
| 其他应收款合计 | 1,680,560.19 | 966,732.65 | 936,398.27 | 573,189.36 |
| 存货 | 118,619,574.22 | 109,712,527.83 | 102,912,029.16 | 102,496,942.26 |
| 其他流动资产 | 5,429,564.63 | 4,595,987.71 | 3,821,171.44 | 6,975,984.64 |
| 流动资产合计 | 255,809,131.38 | 254,194,445.12 | 253,694,510.5 | 261,880,362.12 |
| 非流动资产: | | | | |
| 固定资产 | 234,159,712.43 | 232,625,978.1 | 242,855,213.37 | 246,683,172.09 |
| 在建工程 | 4,661,191.18 | 11,610,444.55 | 6,629,351.64 | 6,459,756.67 |
| 使用权资产 | 535,137.65 | 633,025.66 | 756,261.24 | 840,104.11 |
| 无形资产 | 10,588,008.24 | 10,763,861.08 | 10,939,713.94 | 11,115,168.64 |
| 长期待摊费用 | - | - | 101,446.54 | - |
| 递延所得税资产 | 2,629,367.33 | 2,598,482.7 | 2,531,095.93 | 2,601,547.18 |
| 其他非流动资产 | 3,419,484.66 | 2,064,097.68 | 2,205,452.16 | 2,003,186.14 |
| 非流动资产合计 | 255,992,901.49 | 260,295,889.77 | 266,018,534.82 | 269,702,934.83 |
| 资产总计 | 511,802,032.87 | 514,490,334.89 | 519,713,045.32 | 531,583,296.95 |
| 流动负债: | | | | |
| 短期借款 | 20,025,263.89 | 20,014,661.1 | 22,017,208.33 | 21,023,875 |
| 应付票据及应付账款 | 44,230,551.97 | 49,016,305.68 | 42,536,554.63 | 56,681,601.19 |
| 其中：应付票据 | - | - | 1,488,721.97 | 3,906,402.75 |
| 应付账款 | 44,230,551.97 | 49,016,305.68 | 41,047,832.66 | 52,775,198.44 |
| 合同负债 | 4,771,291.81 | 1,103,311.82 | 644,902.34 | 683,005.17 |
| 应付职工薪酬 | 2,554,397.79 | 2,313,350.62 | 2,280,522.13 | 3,761,007.6 |
| 应交税费 | 214,661.36 | 143,993.34 | 169,616.07 | 173,821.3 |
| 其他应付款合计 | 10,202,569.14 | 15,184,822.24 | 16,325,019.75 | 16,559,073.42 |
| 一年内到期的非流动负债 | 342,456.73 | 353,115.87 | 351,949.76 | 377,591.68 |
| 其他流动负债 | 620,267.94 | 923,377.09 | 83,837.3 | 390,224.54 |
| 流动负债合计 | 82,961,460.63 | 89,052,937.76 | 84,409,610.31 | 99,650,199.9 |
| 非流动负债: | | | | |
| 租赁负债 | 328,649.5 | 380,310.92 | 444,427.73 | 486,202.16 |
| 递延收益 | 12,634,918.08 | 13,024,288.02 | 12,633,989.62 | 12,983,384.56 |
| 非流动负债合计 | 12,963,567.58 | 13,404,598.94 | 13,078,417.35 | 13,469,586.72 |
| 负债合计 | 95,925,028.21 | 102,457,536.7 | 97,488,027.66 | 113,119,786.62 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 100,474,603 | 100,474,603 | 100,717,495 | 100,717,495 |
| 资本公积 | 197,160,967.84 | 196,401,664.54 | 196,390,468.6 | 195,631,165.3 |
| 减:库存股 | 6,305,753.94 | 6,305,753.94 | 7,296,753.3 | 7,296,753.3 |
| 其他综合收益 | -201,396.51 | -176,020.56 | -129,607.5 | -81,529.9 |
| 专项储备 | 9,731,230.5 | 8,837,376.83 | 7,967,546.4 | 7,096,901.72 |
| 盈余公积 | 19,894,471.41 | 19,894,471.41 | 19,894,471.41 | 19,894,471.41 |
| 未分配利润 | 94,575,222.07 | 92,317,383.46 | 104,230,587.83 | 102,025,914.75 |
| 归属于母公司股东权益合计 | 415,329,344.37 | 411,443,724.74 | 421,774,208.44 | 417,987,664.98 |
| 少数股东权益 | 547,660.29 | 589,073.45 | 450,809.22 | 475,845.35 |
| 股东权益合计 | 415,877,004.66 | 412,032,798.19 | 422,225,017.66 | 418,463,510.33 |
| 负债和股东权益合计 | 511,802,032.87 | 514,490,334.89 | 519,713,045.32 | 531,583,296.95 |
| 公告日期 | 2026-10-27 | 2026-08-27 | 2026-04-29 | 2026-04-15 |
| 审计意见(境内) | | | | 标准无保留意见 |